Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Truking Technology Limited (300358.SZ)
CNY8.40
+0.15 (+1.82%)
CN SHZ Healthcare Medical - Instruments & Supplies
Address
No.1 Xinkang Road 410600
Changsha, CN
Changsha, CN
CEO
Yue Tang
Website
truking.cn
IPO
2014-01-21
ISIN CNE100001R41
Description
Truking Technology Limited, established in 2000 and headquartered in Changsha, China, specializes in the research, development, and innovation of machinery for the pharmaceutical and medical industries. The company delivers end-to-end manufacturing solutions for diverse sterile products, encompassing lyophilization, injectable ampoules and vials (for both liquid and powder forms), pre-filling and sealing operations, plastic bottle blow-fill-seal technology, cartridges, non-PVC soft bags, and glass infusion bottles. Its offerings also include specialized fluid processing systems, advanced isolating systems, and dedicated lyophilization laboratories. Operating with a significant international footprint, Truking Technology distributes its products to approximately 40 countries and regions across Asia, Europe, South America, and other global markets.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY8.40
+0.15 (+1.82%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
19M
Beta
0.69
Float Shares
485.97M
Free Float %
82.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.44% | -7.28% | -14.10% | -26.36% | -10.34% | -14.10% | +12.28% | -44.71% | -58.37% | -54.91% | -18.43% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
8.40
DCF (Levered)
0.26
-96.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-12 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.33
Distress
Piotroski F-Score
8 / 9
Strong
MOAT Score
2 / 10
No MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%-1.1% Q1'26: +2.4% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+155.8% ★ Q1'26: +747.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+6.2% Q1'26: -16.0% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+5.5% Q1'26: +6.2% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+6.8% ★ Q1'26: +5.1% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+1.1% Q1'26: +22.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×2.21× ★ Q1'26: 6.89× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
974.83M
est: 976.00M (-0.1%)
|
975.04M
est: 976.00M (-0.1%)
|
1.28B
est: 1.26B (+1.7%)
|
1.63B
est: 1.54B (+6.2%)
|
3.14B
est: 1.96B (+60.1%)
|
3.58B
est: 2.29B (+56.4%)
|
5.07B
est.
|
5.26B
est: 6.36B (-17.2%)
|
6.45B
est: 6.33B (+1.9%)
|
6.85B
est: 6.33B (+8.3%)
|
5.83B
est: 6.38B (-8.6%)
|
5.76B
est: 5.26B (+9.5%)
|
5.59B
5.59B – 5.59B
+6.3% YoY
|
6.34B
6.34B – 6.34B
+13.3% YoY
|
| EBITDA |
221.32M
est: 89.94M (+146.1%)
|
196.81M
est: 89.94M (+118.8%)
|
249.36M
est: 116.02M (+114.9%)
|
120.68M
est: 141.55M (-14.7%)
|
230.77M
est: 180.71M (+27.7%)
|
419.10M
est: 210.66M (+98.9%)
|
466.75M
est.
|
839.91M
est: 585.72M (+43.4%)
|
799.69M
est: 536.95M (+48.9%)
|
564.98M
est: 536.95M (+5.2%)
|
-280.29M
est: 541.53M (-151.8%)
|
612.53M
est: 446.80M (+37.1%)
|
474.73M
474.73M – 474.73M
+6.2% YoY
|
537.79M
537.79M – 537.79M
+13.3% YoY
|
| EBIT |
176.69M
est: 50.41M (+250.5%)
|
139.48M
est: 50.41M (+176.7%)
|
188.99M
est: 65.02M (+190.7%)
|
59.92M
est: 79.33M (-24.5%)
|
102.74M
est: 101.28M (+1.4%)
|
276.52M
est: 118.06M (+134.2%)
|
261.59M
est.
|
665.04M
est: 328.26M (+102.6%)
|
602.38M
est: 299.43M (+101.2%)
|
340.35M
est: 299.43M (+13.7%)
|
-513.79M
est: 301.98M (-270.1%)
|
318.36M
est: 249.16M (+27.8%)
|
264.73M
264.73M – 264.73M
+6.3% YoY
|
299.90M
299.90M – 299.90M
+13.3% YoY
|
| Net Income |
153.39M
est: 236.50M (-35.1%)
|
120.06M
est: 236.50M (-49.2%)
|
160.40M
est: 271.55M (-40.9%)
|
41.31M
est: 242.03M (-82.9%)
|
65.19M
est: 366.00M (-82.2%)
|
200.53M
est: 318.77M (-37.1%)
|
554.90M
est.
|
566.41M
est: 631.64M (-10.3%)
|
567.45M
est: -33.14M (+1,812.5%)
|
317.08M
est: -33.14M (+1,056.9%)
|
-452.66M
est: 41.79M (-1,183.0%)
|
254.65M
est: 17.91M (+1,321.7%)
|
95.53M
95.53M – 95.53M
+433.3% YoY
|
167.18M
167.18M – 167.18M
+75.0% YoY
|
| SGA |
253.18M
est: 110.24M (+129.7%)
|
285.44M
est: 110.24M (+158.9%)
|
232.22M
est: 142.21M (+63.3%)
|
275.54M
est: 173.49M (+58.8%)
|
558.40M
est: 221.50M (+152.1%)
|
665.01M
est: 258.21M (+157.5%)
|
572.10M
est.
|
1.02B
est: 717.92M (+41.6%)
|
1.17B
est: 1.00B (+16.1%)
|
1.16B
est: 1.00B (+15.6%)
|
1.12B
est: 1.01B (+11.0%)
|
330.39M
est: 835.60M (-60.5%)
|
887.82M
887.82M – 887.82M
+6.3% YoY
|
1.01B
1.01B – 1.01B
+13.3% YoY
|
| EPS |
0.39
est: 0.40 (-2.7%)
|
0.28
est: 0.40 (-30.1%)
|
0.37
est: 0.46 (-19.6%)
|
0.09
est: 0.41 (-78.0%)
|
0.12
est: 0.62 (-80.6%)
|
0.38
est: 0.54 (-29.6%)
|
0.94
est.
|
1.01
est: 1.07 (-5.6%)
|
0.99
est: -0.06 (+1,883.9%)
|
0.55
est: -0.06 (+1,091.0%)
|
-0.77
est: 0.07 (-1,200.0%)
|
0.43
est: 0.03 (+1,333.3%)
|
0.16
0.16 – 0.16
+433.3% YoY
|
0.28
0.28 – 0.28
+75.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-14 | B | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 2/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 2/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 2/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
22.13M
OE per share TTM
-0.03
Owner's Yield
0.36%
Maintenance CapEx ratio
55.67%
Maint CapEx / Avg PPE
37.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 16 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 69.2K | 0.46% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 161.9K | 0.39% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 87.6K | 0.29% |
| 4 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 5.6K | 0.48% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 12.7K | 0.26% |
| 6 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 628.6K | 0.06% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 45.0K | 0.28% |
| 8 | Vanguard Total International Stock ETF VXUS | 0.00% | 814.1K | 0.05% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 6.0K | 0.10% |
| 10 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 1.0K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
45.4K
Shares Outstanding
590.23M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fan Yun Zeng | Executive President & Vice-Chairman | — | male |
| Fei Yue Zhou | Co-President & Director | — | male |
| Jing Ying Zhou | Co-President | — | female |
| Shui Liu | Co-President | — | female |
| Wenlu Yang | Co-President & Director | — | male |
| Yu Ting Huang | Board Secretary | — | male |
| Yuan Jiang | Accounting Supervisor | — | — |
| Yuan Long Zhong | Co-President | — | male |
| Yue Tang | President & Chairman | — | male |
| Yun Hong Xiao | Chief Financial Officer, Co-President & Director | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300358.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
